Health and Welfare Statistics Association: Cause of death. Annual statistical report of National Health Conditions. J Health Welf Stat 2003; 50 ( Suppl): 46–51 ( in Japanese).
Ueshima H : Reduction of blood pressure and cardiovascular mortality in Japan. J Blood Press (Ketsuatsu) 1994; 1: 194–201 ( in Japanese).
Kubo M, Kiyohara Y, Kato I, et al: Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama study. Stroke 2003; 34: 2349–2354.
Kitamura A, Iso H, Iida M, et al: Trends in the indicence of coronary heart disease and stroke and the prevalence of cardiovascular risk factors among Japanese men from 1963 to 1994. Am J Med 2002; 112: 104–109.
Vital and Health Statistics Division, Statistics and Information Department, Ministry of Health, Labor and Welfare (ed): Vital Statistics of Japan 2002, Vol 1. Tokyo, Health and Welfare Statistics Association, 2004 ( in Japanese).
Isomura K : Investigation of long-term follow-up system based on community, in: Annual Report of National Project Team Supported by the Research Grant for Cardiovascular Desease from Ministry of Health and Welfare, Japan in 1993. Osaka, National Cardiovascular Center, 1994 ( in Japanese).
Kimura Y, Takishita S, Muratani H, et al: Demographic study of first-ever stroke and acute myocardial infarction in Okinawa, Japan. Intern Med 1998; 37: 736–745.
Asia Pacific Cohort Studies Collaboration: Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens 2003; 21: 707–716.
Tanizaki Y, Kiyohara Y, Kato I, et al: Relationship between blood pressure based on JNC VI classification and incidence of different types of stroke in the Hisayama study, in: The Abstract Book of the 21st Annual Scientific Meeting of Japanese Society of Hypertension. 1998, p 22 ( in Japanese).
NIPPON DATA 80 Research Group: Impact of elevated blood pressure on mortality from all causes, cardiovascular diseases, heart disease and stroke among Japanese: 14 year follow-up of randomly selected population from Japanese. Nippon Data 80. J Hum Hypertens 2003; 17: 851–857.
Tanizaki Y, Kiyohara Y, Kato I, et al: Incidence and risk factors for subtypes of cerebral infarction in a general population. The Hisayama Study. Stroke 2000; 31: 2616–2622.
Health Japan 21 Planning Committee: Report of Action Plan-Making Meeting of Health Japan 21 (National Health Promotion in the 21st Century). Tokyo, Japan Health Promotion & Fitness Foundation, 2000 ( in Japanese).
Arima H, Tanizaki Y, Kiyohara Y, et al: Validity of the JNC VI recommendations for the management of hypertension in a general population of Japanese elderly. The Hisayama Study. Arch Intern Med 2003; 163: 361–366.
Prospective Studies Collaboration: Age-specific relevance of usual blood pressure to vascular morality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903–1913.
Thorvaldsen P, Asplund K, Kuulasmaa K, Rajakangas AM, Schroll M, for the WHO MONICA Project: Stroke incidence, case fatality, and mortality in the WHO MONICA project. Stroke 1995; 26: 361–367.
Kita Y, Okayama A, Ueshima H, et al: Stroke incidence and case fatality in Shiga, Japan 1989-1993. Int J Epidemiol 1999; 28: 1059–1065.
INTERSALT Cooperative Research Group: INTERSALT: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion. BMJ 1998; 297: 319–329.
Nakagawa H, Morikawa Y, Okayama A, et al: Trends in blood pressure and urinary sodium and potassium excretion in Japan: reinvestigation in the 8th year after the INTERSALT study. J Hum Hypertens 1999; 13: 735–741.
Stamler J : INTERMAP. J Hum Hypertens 2003; 17 ( Special Issue): 587–775.
Ueshima H : Long-term intervention study to prevent common disease in young and middle-aged subjects, in: Annual Report of Comprehensive and Contributory Studies in 2000. 2001 ( in Japanese).
Kojima S, Funaki A, Sawabe K, Takakuwa K : Changes in dietary habit and cardiovascular disease in rural area in Akita from 1950 to 1960, in Komachi Y, Isomura K, Kojima S, Shimamoto T, Tanaka H, Ozawa H (eds): Changes in Cardiovascular Disease. Tokyo, Hokendojinsha Inc, 1987, pp 120–138 ( in Japanese).
INTERSALT Cooperative Research Group: INTERSALT. Appendix tables. J Hum Hypertens 1989; 3: 331–407.
Sacks FM, Svetkey LP, Vollmer WM, et al, DASHSodium Collaborative Research Group: Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med 2001; 344: 3–10.
Research Committee of Cardiovascular Diseases Prevention: The 5th Report of National Cardiovascular Survey of Japan. Tokyo, Chuohoki Publishers, 2002 ( in Japanese).
Public Health Division, Ministry of Health and Welfare: 1980 National Cardiovascular Survey of Japan. Tokyo, Japan Heart Foundation, 1982 ( in Japanese).
Public Health Division, Ministry of Health and Welfare: The 4th Report of National Cardiovascular Survey of Japan. Osaka, Japan Cardiovascular Research Foundation, and Tokyo, Japanese Association for Cerebro-Cardiovascular Disease Control, 1993 ( in Japanese).
Hozawa A, Ohkubo T, Kikuya M, et al: Blood pressure control assessed by home, ambulatory and conventional blood pressure measurements in the Japanese general population: the Ohasama study. Hypertens Res 2002; 25: 57–63.
Okubo T, Kohara T, Funahashi H, Kikuya M, Hashimoto J, Imai Y : J-HOME study: status in April 2003. Ther Res 2003; 24: 1849–1855 ( in Japanese).
Chobanian AV, Bakris GL, Black HR, et al, the National High Blood Pressure Education Program Coordination Committee: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003; 289: 2560–2572.
Stamler J, Rose G, Stamler R, Elliott P, Dyer A, Marmot M : INTERSALT study findings: public health and medical care implications. Hypertension 1989; 14: 570–577.
Tsunematsu N, Ueshima H, Okuda N, et al, Japanese Subgroup of INTERMAP: The actual amount of reductions in salt intake in humans on a restricted salt diet compared with those on an unrestricted salt diet: from INTERMAP JAPAN. Jpn J Cardiovasc Dis Prev 2004; 14: 149–155 ( in Japanese).
Smits P, Thien T, Van't Laar A : The cardiovascular effects of regular and decaffeinated coffee. Br J Clin Pharmacol 1985; 19: 852–854.
Minami J, Ishimitsu T, Matsuoka H : Effects of smoking cessation on blood pressure and heart rate variability in habitual smokers. Hypertension 1999; 33: 586–590.
Prisant LM, Alpert BS, Robbins CB, et al: American National Standard for Nonautomated Sphygmomanometers summary report. Am J Hypertens 1995; 8: 210–213.
Menard J, Chatellier G, Day M, Vaur L : Self-measurement of blood pressure at home to evaluate drug effects by the trough: peak ratio. J Hypertens Suppl 1994; 12 ( 8): S21–S25.
Imai Y, Otsuka K, Kawano Y, et al, on behalf of the Japanese Society of Hypertension: Japanese Society of Hypertension (JSH) guidelines for self-monitoring of blood pressure at home. Hypertens Res 2003; 26: 771–782.
Imai Y, Munakata M, Yoshino H, et al: Seasonal variation in blood pressure in normotensive subjects studied by home measurements. Clin Sci 1996; 95: 55–60.
Kikuya M, Chonan K, Imai Y, Goto E, Ishii M : Research group to assess the validity of automated blood pressure measurement devices in Japan: accuracy and reliability of wrist-cuff devices for self-measurement of blood pressure. J Hypertens 2002; 20: 629–638.
Ishimitsu T, Matsuoka H, Minami J, Kawano Y : Investigation of usefulness of home blood pressure in patients with hypertension. Ther Res 1997; 18: 488–493 ( in Japanese).
Ishii M, Goto E : Accuracy control of home blood pressure monitor. Ther Res 1998; 19: 56–59 ( in Japanese).
Ohkubo T, Imai Y, Tsuji I, et al: Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement: a population-based observation in Ohasama, Japan. J Hypertens 1998; 16: 971–975.
Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413–2446.
Guideline Committee: 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–1053.
Guidelines Subcommittee: 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999; 17: 151–183.
Tsuji I, Imai Y, Nagai K, Ohkubo T, Watanabe N, Minami N : Proposal of reference values for home blood pressure measurement. Prognostic criteria based on a prospective observation of the general population in Ohasama, Japan.. Am J Hypertens 1997; 10: 409–419.
Imai Y, Ohkubo T, Tsuji I, et al: Prognostic value of ambulatory and home blood pressure measurements in comparison to screening blood pressure measurements: a pilot study in Ohasama. Blood Press Monit 1996; 1 ( Suppl 2): S51–S58.
Guidelines Subcommittee of the Japanese Society of Hypertension: Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2000). Tokyo, Japanese Society of Hypertension, 2000 ( in Japanese).
Fujiwara T, Nishimura T, Ohkubo T, Imai Y : Rationale and design of HOMED-BP study: hypertension objective treatment based on measurement by electrical devices of blood pressure study. Blood Press Monit 2002; 7: 77–82.
Imai Y, Abe K, Sasaki S, et al: Determination of clinical accuracy and nocturnal blood pressure pattern by new portable device for monitoring indirect ambulatory blood pressure. Am J Hypertens 1990; 3: 293–301.
Imai Y, Sasaki S, Minami N, et al: The accuracy and performance of the A & D TM2421, a new ambulatory blood pressure monitoring device based on the cuff-oscillometric method and the Korotkoff sound technique. Am J Hypertens 1992; 5: 719–726.
Kuwajima I, Nishinaga M, Kanamaru A : The accuracy and clinical performance of a new compact ambulatory blood pressure monitoring device, the ES-H531. Am J Hypertens 1998; 11: 1328–1333.
Shimada K, Imai Y, Kuwajima I, et al: Guidelines for 24-hour ambulatory blood pressure monitoring (ABPM). Jpn Circ J 2000; 64 ( Suppl 5): 1207–1248 ( in Japanese).
Sokolow M, Werdegar D, Kain HK, Hinman AT : Relationship between level of blood pressure measured casually and by portable recorders and severity of complications in essential hypertension. Circulation 1966; 34: 279–298.
Mancia G, Zanchetti A, Agabiti-Rosei E, et al: Ambula tory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. SAMPLE Study Group. Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation. Circulation 1997; 95: 1464–1470.
Imai Y, Ohkubo T, Sakuma M, et al: Predictive power of screening BP, ambulatory BP and BP measured at home for overall cardiovascular mortality: a prospective observation in a cohort of northern Japan, Ohasama. Blood Press Monit 1996; 1: 251–254.
Ohkubo T, Hozawa A, Nagai K, et al: Prediction of stroke by ambulatory blood pressure monitoring versus screening blood pressure measurements in a general population: the Ohasama study. J Hypertens 2000; 18: 847–854.
Verdecchia P, Schillaci G, Reboldi G, Franklin SS, Porcellati C : Different prognostic impact of 24-hour mean blood pressure and pulse pressure on stroke and coronary artery disease in essential hypertension. Circulation 2001; 103: 2579–2584.
Suzuki Y, Kuwajima I, Aono T, et al: Prognostic value of nighttime blood pressure in the elderly: a prospective study of 24-hour blood pressure. Hypertens Res 2000; 23: 323–330.
Staessen JA, Thijs L, Fagard R, et al, Systolic Hypertension in Europe Trial Investigators: Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. JAMA 1999; 282: 539–546.
Shimada K, Kawamoto A, Matsubayashi K, Ozawa T : Silent cerebrovascular disease in the elderly. Correlation with ambulatory blood pressure. Hypertension 1990; 16: 692–699.
Verdecchia P, Schillaci G, Guerrieri M, et al: Circadian blood pressure and left ventricular hypertrophy in essential hypertension. Circulation 1990; 81: 528–536.
Bianchi S, Bigazzi R, Baldari G, Sgherri G, Campese VM : Diurnal variations of blood pressure and microalbuminuria in essential hypertension. Am J Hypertens 1994; 7: 23–29.
Verdecchia P, Porcellati C, Schillaci G, et al: Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension 1994; 24: 793–801.
Shimada K, Imai Y, Kuwajima I, Abe K : Patients characteristics and effects of the long-term acting calcium channel blocker barnidipine on circadian blood pressure changes: results of the Japanese Multicenter Study on Barnidipine with Ambulatory Blood Pressure Monitoring. Blood Press Monit 2001; 6 ( Suppl 2): S25–S30.
Ohkubo T, Hozawa A, Yamaguchi J, et al: Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-hour blood pressure: the Ohasama study. J Hypertens 2002; 20: 1–7.
Kario K, Matsuo T, Kobayashi H, Imiya M, Matsuo M, Shimada K : Nocturnal fall of blood pressure and silent cerebrovascular damage in elderly hypertensive patients. Advanced silent cerebrovascular damage in extreme dippers. Hypertension 1996; 27: 130–135.
Ohkubo T, Imai Y, Tsuji I, et al: Relation between nocturnal decline in blood pressure and mortality: the Ohasama Study. Am J Hypertens 1997; 10: 1201–1207.
Chonan K, Hashimoto J, Ohkubo T, et al: Insufficient duration of action of antihypertensive drugs mediates high blood pressure in the morning in hypertensive population: the Ohasama Study. Clin Exp Hypertens 2002; 24: 261–275.
Kario K, Pickering TG, Umeda Y, et al: Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation 2003; 107: 1401–1406.
Kawasaki T, Uezono K : An attempt for establishment of standard values for circadian blood pressure on the basis of clinically healthy Japanese, in Omae T, Kawasaki T (ed): Clinical Practice of Blood Pressure Monitoring. Tokyo, Igaku-Shoin Ltd, 1993, pp 181–189 ( in Japanese).
Ohkubo T, Imai Y, Tsuji I, et al: Reference values for 24-hour ambulatory blood pressure monitoring based on a prognostic criterion: the Ohasama Study. Hypertension 1998; 32: 255–259.
Kikuya M, Hozawa A, Ohkubo T, et al: Prognostic significance of blood pressure and heart rate variabilities. Hypertension 2000; 36: 901–906.
World Health Organization, International Society of Hypertension Writing Group: 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983–1992.
Ueda K, Omae T, Hasuo Y, et al: Prognosis and outcome of elderly hypertensives in a Japanese community: results from a long-term prospective study. J Hypertens 1988; 6: 991–997.
Shimamoto K : A recent trend in management and treatment of hypertension in Japan in special reference to JNCVI. J Jpn Soc Intern Med 1999; 88: 401–405 ( in Japanese).
Kassai B, Gueyffier F, Boissed J-P, Boutitie F, Cucherat M : Absolute benefit, number needed to treat and gain in life expectancy: which efficacy indices for measuring the treatment benefit? J Clin Epidemiol 2003; 56: 977–982.
Fujishima M, Kiyohara Y, Kato I, et al: Diabetes and cardiovascular disease in a prospective population survey in Japan: the Hisayama Study. Diabetes 1996; 45 ( Suppl 3): S14–S16.
Committee for Statistical Survey, Japanese Society for Dialysis Therapy: The current state of dialysis treatment in Japan (as of Dec. 31, 2001). J Jpn Soc Dial Ther 2003; 36: 1–31 ( in Japanese).
Hansson L, Zanchetti A, Carruthers SG, et al: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755–1762.
UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703–713.
Schrier RW, Estacio RO, Esler A, Mehler P : Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and stroke. Kidney Int 2002; 61: 1086–1097.
Omata K, Kanazawa M, Sato T, Abe F, Saito T, Abe K : Therapeutic advantages of angiotensin converting enzyme inhibitors in chronic renal disease. Kidney Int Suppl 1996; 55: S57–S62.
Brenner BM, Cooper ME, de Zeeuw D, et al, RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–869.
Adler AI, Stratton IM, Neil HA, et al: Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes: UKPDS 36. BMJ 2000; 321: 412–419.
Franklin SS, Khan SA, Wong ND, Larson MG, Levy D : Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham heart study. Circulation 1999; 100: 354–360.
Kario K, Shimada K, Schwartz JE, Matsuo T, Hoshide S, Pickering TG : Silent and clinically overt stroke in older Japanese subjects with white-coat and sustained hypertension. J Cardiol 2002; 39: 52–54.
Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP : Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561–1566.
Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D : Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 1999; 56: 2214–2219.
O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr, Cardiovascular Health Study Collaborative Research Group: Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 1999; 340: 14–22.
Safar ME, Levy BI, Struijker-Boudier H : Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. Circulation 2003; 107: 2864–2869.
Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH : Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98: 731–733.
Lever AF, Ramsey LE : Treatment of hypertension in the elderly. J Hypertens 1995; 13: 571–579.
Moser M, Hebert PR : Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol 1996; 27: 1214–1218.
Psaty BM, Smith NL, Siscovick DS, et al: Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic reviews and meta-analysis. JAMA 1997; 277: 739–745.
Collins R, Peto R : Antihypertensive drug therapy: effects on stroke and coronary heart disease, in Swales JD (ed): Textbook of Hypertension. London, Blackwell Scientific Publication, 1994, pp 1156–1164.
Whelton PK, He J : Blood pressure reduction, in Hennekens CH (ed): Clinical Trials in Cardiovascular Disease: A Companion to Braunwald's Heart Disease. Philadelphia, WB Saunders, 1999, pp 341–359.
Collins R, Peto R, MacMahon S, et al: Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827–839.
Health and Welfare Statistics Association: Annual Statistical Report of National Health Conditions. J Health Welf Stat 2003; 50 ( Suppl): 412–413 ( in Japanese).
Staessen JA, Gasowski J, Wang JG, et al: Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000; 355: 865–872.
Gueyffier F, Boutitie F, Boissel JP, et al: Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. Results from a meta-analysis of individual patient data in randomized controlled trials. Ann Intern Med 1997; 126: 761–767.
MacMahon S, Rodgers A : The effects of blood pressure reduction in older patients: an overview of five randomized controlled trials in elderly hypertensives. Clin Exp Hypertens 1993; 15: 967–978.
Lewington S, Clarke R, Qizilbash N, Peto R, Collins R : Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Prospective Studies Collaboration. Lancet 2002; 360: 1903–1913.
Vasan RS, Larson MG, Leip EP, et al: Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345: 1291–1297.
Chobanian AV, Bakris GL, Black HR, et al, National High Blood Pressure Education Program Coordinating Committee: Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206–1252.
Takagi S, Saitoh S, Nakano M, et al: Relationship between blood pressure level and mortality rate: an 18-year study conducted in two rural communities in Japan. J Hypertens 2000; 18: 139–144.
PROGRESS Collaborative Study Group: Randomised trial of perindopril based blood pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–1041.
The Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145–153.
Zanchetti A, Hansson L, Clement D, et al, HOT Study Group: Benefits and risks of more intensive blood pressure lowering in hypertensive patients of the HOT study with different risk profiles: does a J-shaped curve exist in smokers? J Hypertens 2003; 21: 797–804.
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–2997.
Appel LJ, Moore TJ, Obarzanek E, et al, DASH Collaborative Research Group: A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med 1997; 336: 1117–1124.
Whelton PK, Appel LJ, Espeland MA, et al: Sodium reduction and weight loss in the treatment of hypertension in older persons. A randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). JAMA 1998; 279: 839–846.
Arakawa K : Exercise treatment in hypertension (all of hypertension). J Clin Exp Med (Igaku No Ayumi) 1999; 189: 680–684 ( in Japanese).
Hayashi T, Tsumura K, Suematsu C, Okada K, Fujii S, Endo G : Walking to work and risk for hypertension in men: the Osaka Health Survey. Ann Intern Med 1999; 130: 21–26.
Neaton JD, Grimm RH Jr, Prineas RJ, et al, for the Treatment of Hypertension Study Group: Treatment of mild hypertension study. Final results. JAMA 1993; 270: 713–724.
Singer DRJ, Markandu ND, Cappuccio FP, Miller MA, Sagnella GA, MacGregor GA : Reduction of salt intake during converting enzyme inhibitor treatment compared with addition of a thiazide. Hypertension 1995; 25: 1042–1044.
Dahlof B, Devereux RB, Kjeldsen SE, et al, LIFE Study Group: Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003.
Lithell H, Hansson L, Skoog I, et al, SCOPE Study Group: The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized doubleblind intervention trial. J Hypertens 2003; 21: 875–886.
Julius S, Kjeldsen SE, Weber M, et al, VALUE Trial Group: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022–2031.
Weber MA, Julius S, Kjeldsen SE, et al: Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004; 363: 2049–2051.
Fujii J, Imataka K : Maintenance of long-term treatment and compliance, in: Long-Term Treatment of Hypertension. Tokyo, Chugai Igakusha, 1988, pp 149–160 ( in Japanese).
Wing LMH, Brown MA, Beilin LJ, Ryan P, Reid CM, ANBP2 Management Committee and Investigators : 'Reverse white-coat hypertension' in older hypertensives. J Hypertens 2002; 20: 639–644.
Saito I, Saruta T : Effect of education through a periodic newsletter on persistence with antihypertensive therapy. Hypertens Res 2003; 26: 159–162.
Yoshida K, Matsuoka H, Omae T, Fujii J : Patient-hospital relationship and quality of life in elderly patients with hypertension. Hypertens Res 1995; 18: 77–83.
Dimenas ES, Wiklund IK, Dahlhof CG, Lindvall KG, Olofsson BK, de Faire UH : Differences in the subjective well-being and symptoms of normotensives, borderline hypertensives and hypertensives. J Hypertens 1989; 7: 885–890.
Mikami H, Ogihara T : Quality of life in the pharmacologically treated elderly patients. Jpn J Geriat 1999; 36: 186–190 ( in Japanese).
Croog SE, Levine S, Testa MA, et al: The effects of antihypertensive therapy on the quality of life. N Engl J Med 1986; 314: 1657–1664.
Beto JA, Bansal VK : Quality of life in treatment of hypertension. A meta-analysis of clinical trials. Am J Hypertens 1992; 5: 125–133.
Hjemdahl P, Wiklund IK : Quality of life on antihypertensive drug therapy: scientific end-point or marketing exercise? J Hypertens 1992; 10: 1437–1446.
Della Chiesa A, Pfiffner D, Meier B, Hess OM : Sexual activity in hypertensive men. J Hum Hypertens 2003; 17: 515–521.
Grimm RH Jr, Grandits GA, Prineas RJ, et al: Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS). Hypertension 1997; 29: 8–14.
Materson BJ, Reda DJ, Cushman WC, et al, The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents : Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. N Engl J Med 1993; 328: 914–921.
Kloner RA, Brown M, Prisant LM, Collins M, Sildenafil Study Group : Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Am J Hypertens 2001; 14: 70–73.
Eaton SB, Eaton SB 3rd, Konner MJ, Shostak M : An evolutionary perspective enhances understanding of human nutritional requirements. J Nutr 1996; 126: 1732–1740.
Office of the Measures to Fight Common Disease, Community Health, Health Promotion and Nutrition Division, Healthcare Department, Ministry of Health, Labor and Welfare: Present Status of Nutrition in Japan: Version of the 14th Year of Heisei Era. Tokyo, Dai-ichi Shuppan Publishing Co Ltd, 2004 ( in Japanese).
Tochikubo O, Sasaki O, Umemura S, Kaneko Y : Management of hypertension in high school students by using new salt titrator tape. Hypertension 1986; 8: 1164–1171.
Fujita T, Ando K, Ogata E : Systemic and regional hemodynamics in patients with salt-sensitive hypertension. Hypertension 1990; 16: 235–244.
Morimoto A, Uzu T, Fujii T, et al: Sodium sensitivity and cardiovascular events with essential hypertension. Lancet 1997; 350: 1734–1737.
Fujita T, Ando K : Hemodynamic and endocrine changes associated with potassium supplementation in sodium-loaded hypertensives. Hypertension 1984; 6: 184–192.
Kawano Y, Matsuoka H, Takishita S, Omae T : Effects of magnesium supplementation in hypertensive patients: assessment by office, home, and ambulatory blood pressures. Hypertension 1998; 32: 260–265.
Iso H, Terao A, Kitamura A, et al: Calcium intake and blood pressure in seven Japanese population. Am J Epidemiol 1991; 133: 776–783.
Zhou BF, Stamler J, Dennis B, et al, for the INTERMAP Research Group : Nutrient intakes of middle-aged men and women in China, Japan, United Kingdom, and United States in the last 1990s: the INTERMAP Study. J Hum Hypertens 2003; 17: 623–630.
Matsuzawa Y, Inoue S, Ikeda Y, et al: New diagnostic criteria of obesity and "obesity disease". J Jpn Soc Study Obes 2000; 6: 18–28 ( in Japanese).
Miyao M, Furuta M, Sakakibara H, et al: Analysis of factors related to hypertension in Japanese middle-aged male workers. J Hum Hypertens 1992; 6: 193–197.
Kawamura M, Adachi T, Nakajima J, Fujiwara T, Hiramori K : Factors that affect calorie-sensitive and calorie-insensitive reduction in blood pressure during shortterm calorie reduction in overweight women. Hypertension 1996; 27: 408–413.
Masuo K, Mikami H, Ogihara T, Tuck ML : Weight reduction and pharmacologic treatment in obese hypertensives. Am J Hypertens 2001; 14: 530–538.
Sasaki S, Higashi Y, Nakagawa K, et al: A low-calorie diet improves endothelium-dependent vasodilation in obese patients with essential hypertension. Am J Hypertens 2002; 15: 302–309.
Hsieh SD, Yoshinaga H, Muto T, Sakurai Y : Regular physical activity and coronary risk factors in Japanese men. Circulation 1998; 97: 661–665.
Tashiro E, Miura S, Koga M, et al: Crossover comparison between the depressor effects of low and high work-rate exercise in mild hypertension. Clin Exp Pharmacol Physiol 1993; 20: 689–696.
Ishikawa-Takata K, Ohta T, Tanaka H : How much exercise is required to reduce blood pressure in essential hypertensives: a dose-response study. Am J Hypertens 2003; 16: 629–633.
Kiyonaga A, Arakawa K, Tanaka H, Shindo M : Blood pressure and hormonal responses to aerobic exercise. Hypertension 1985; 7: 125–131.
The Japanese Society of Nephrology: Guideline for life style and dietary therapy for patients with kidney disease. Jpn J Nephrol 1997; 39: 1–37 ( in Japanese).
Motoyama M, Sumani Y, Kinoshita F, et al: Blood pressure lowering effect of low intensity aerobic training in elderly hypertensive patients. Med Sci Sports Exerc 1998; 30: 818–823.
Ohkubo T, Hozawa A, Nagatomi R, et al: Effects of exercise training on home blood pressure values in older adults: a randomized controlled trial. J Hypertens 2001; 19: 1045–1052.
Ueshima H, Ozawa H, Baba S, et al: Alcohol drinking and high blood pressure: data from a 1980 National Cardiovascular Survey of Japan. J Clin Epidemiol 1992; 45: 667–673.
Marmot MG, Elliott P, Shipley MJ, et al: Alcohol and blood pressure: the INTERSALT study. BMJ 1994; 308: 1263–1267.
Ueshima H, Mikawa K, Baba S, et al: Effect of reduced alcohol consumption of native Japanese to American men. J Clin Epidemiol 1990; 43: 1407–1414.
Kiyohara Y, Ueda K, Fujishima M : Smoking and cardiovascular disease in the general population in Japan. J Hypertens Suppl 1990; 8 ( 5): S9–S15.
Sato I, Nishida M, Okita K, et al: Beneficial effect of stopping smoking on future cardiac events in male smokers with previous myocardial infarction. Jpn Circ J 1992; 56: 217–222.
Kim MK, Sasaki S, Sasazuki S, Ohkubo S, Hayashi M, Tsugane S : Lack of long-term effect of vitamin C supplementation on blood pressure. Hypertension 2002; 40: 797–803.
Brown BG, Cheung MC, Lee AC, Zhao X-Q, Chait A : Antioxidant vitamins and lipid therapy.end of a long romance? Arterioscler Thromb Vasc Biol 2002; 22: 1535–1546.
The Eurowinter Group: Cold exposure and winter mortality from ischemic heart disease, cerebrovascular disease, respiratory disease, and all cause in warm and cold regions of Europe. Lancet 1997; 349: 1341–1346.
Appel LJ, Champagne CM, Harsha DW, et al, Writing Group of the PREMIER Collaborative Research Group : Effects of comprehensive lifestyle modification on blood pressure control. JAMA 2003; 289: 2083–2093.
Blood Pressure Lowering Treatment Trialists' Collaboration: Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527–1535.
Staessen JA, Wang JG, Thijs L : Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens 2003; 21: 1055–1076.
National Intervention Cooperative Study in Elderly Hypertensives Study Group: Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. Hypertension 1999; 34: 1129–1133.
The GLANT Study Group: A 12-month comparison of ACE inhibitor and Ca antagonist therapy in mild to moderate essential hypertension—the GLANT study—.. Hypertens Res 1995; 18: 235–244.
Saito I, Kawabe H, Saruta T, et al: Effects of antihypertensive therapy with a Ca antagonist, an ACE inhibitor and a ß-blocker. Jpn Med J (Nihon Iji Shinpo) 1994; 3683: 27–31 ( in Japanese).
Baba S, the J-MIND Study Group : Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetes. Diabetes Res Clin Pract 2001; 54: 191–201.
Yui Y, Sumiyoshi T, Kodama K, et al, The Japan Multicenter Investigation for Cardiovascular Disease-B (JMICB) Study Group: Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Disease-B (JMIC-B) randomized trial. Hypertens Res 2004; 27: 181–191.
Furberg CD, Psaty BM, Meyer JV : Nifedipine. Doserelated increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1231–1232.
Hayashi K, Kumagai H, Saruta T : Effect of efonidipine and ACE inhibitors on proteinuria in human hypertension with renal impairment. Am J Hypertens 2003; 16: 116–122.
Minami J, Ishimitsu T, Higashi T, Numabe A, Matsuoka H : Comparison between cilnidipine and nisoldipine with respect to effects on blood pressure and heart rate in hypertensive patients. Hypertens Res 1998; 21: 215–219.
Kuramoto K, Ichikawa S, Hirai A, Kanada S, Nakachi T, Ogihara T : Azelnidipine and amlodipine: a comparison of their pharmacokinetics and effects on ambulatory blood pressure. Hypertens Res 2003; 26: 201–208.
Pitt B, Byington RP, Furberg CD, et al: Effect of amlodipine on the progression of atheroscrelosis and the occurrence of clinical events. Circulation 2000; 102: 1503–1510.
Goldberg AI, Dunlay MC, Sweet CS : Safety and tolerability of losartan compared with atenolol, felodipine and angiotensin converting enzyme inhibitors. J Hypertens Suppl 1995; 13 ( 1): S77–S80.
Yoshinaga K, Iimura O, Saruta T, et al: Evaluation of clinical usefulness of MK-954 (losartan potassium) in patients with essential hypertension: double-blind, parallel group-comparison study using enarapril maleate as control drug. J Clin Exp Med (Igaku No Ayumi) 1995; 172: 758–823 ( in Japanese).
Arakawa K, Ogihara T, Iimura O, et al: Evaluation of clinical usefulness of TCV-116 (candesartan cilexetil) in patients with essential hypertension: double blind, parallel group-comparison study using enarapril maleate as control drug. J Clin Ther Med (Rinsho Iyaku) 1996; 12: 2613–2661 ( in Japanese).
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD : The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy: the Collaborative Study Group. N Engl J Med 1993; 329: 1456–1462.
Hasegawa Y, Yamaguchi T, Omae T, Woodward M, Chalmers J, the PROGRESS CT Substudy Investigators : Effects of perindopril-based blood pressure lowering and of patients characteristics on the progression of silent brain infarct: the Perindopril Protection against Recurrent Stroke Study (PROGRESS) CT substudy in Japan. Hypertens Res 2004; 27: 147–156.
Saruta T, Arakawa K, Iimura O, et al: Usefulness of imidapril hydrochloride in the treatment of hypertension with special reference to dry cough: comparison with enarapril maleate: multicenter cooperative study. J New Remedies Clin (Shinyaku To Rinsho) 1998; 47: 249–282 ( in Japanese).
Shah S, Khatri T, Freis ED : Mechanism of antihypertensive effect of thiazide diuretics. Am Heart J 1998; 95: 611–618.
Pitt B, Zannad F, Remme WJ, et al, for the Randomized Aldactone Evaluation Study Investigators : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709–717.
Saruta T, Kageyama S, Ogihara T, et al: Efficacy and safety of the selective aldosterone blocker eplerenone in Japanese patients with hypertension: a randomized, double-blind, placebo-controlled, dose-ranging study. J Clin Hypertens 2004; 6: 175–185.
Saruta T, Suzuki H, Kawamura M, Itoh H : Serum creatine phosphokinase levels during treatment with beta-adrenoreceptor blocking agents. J Cardiovasc Pharmacol 1985; 7: 805–808.
Goto Y, Kozu Y, Kawabe K, et al: Long-term effects of doxazosin mesylate in hypertensive patients with hypercholesterolemia or diabetes or both. J Jpn Physicians Assoc 2001; 16: 46–67 ( in Japanese).
Shinohara Y, Yoshimoto T, Fukuuchi Y, Ishigami S, Joint Committee of Stroke Guideline Development: Guideline for the Management of Stroke in Japan 2004. Tokyo, Kyowa Kikaku, 2004 ( in Japanese).
Broderick JP, Adams HP Jr, Barsan W, et al: Guidelines for the management of spontaneous intracerebral hemorrhage; a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 1999; 30: 905–915.
Adams HP Jr, Brott TG, Crowell RM, et al: Guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 1994; 25: 1901–1914.
Kuriyama Y : CBF (cerebral blood flow) autoregulation and antihypertensive therapy, in Saruta T, Arakawa K, Kokubu T (supervising eds): ACE Inhibitors; Innovative Clinical Applications. Tokyo, Medical Tribune, 1990, pp 89–96 ( in Japanese).
International Society of Hypertension Writing Group: International Society of Hypertension (ISH): Statement on the management of blood pressure in acute stroke. J Hypertens 2003; 21: 665–672.
Osaki Y, Matsubayashi K, Yamasaki M, et al: Post-stroke hypertension correlates with neurologic recovery in patients with acute ischemic stroke. Hypertens Res 1998; 21: 169–173.
Blood Pressure in Acute Stroke Collaboration (BASC): Interventions for Deliberating Altering Blood Pressure in Acute Stroke. The Cochrane Library, Issue 3, 2003. Oxford, Update Software, 2003.
The National Institute of Neurological Disorders and Stroke: Proceedings of National Symposium on Rapid Identification and Treatment of Acute Stroke. NIH Publication 1997, No 97-4239, pp 1–183.
Schrader J, Luders S, Kulschewski A, et al: The ACCESS study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 2003; 34: 1699–1703.
Adams HP Jr, Adams RJ, Brott T, et al, Stroke Council of the American Stroke Association : Guidelines for the early management of patients with ischemic stroke. A scientific statement from the stroke council of the American Heart Association. Stroke 2003; 34: 1056–1083.
Irie K, Yamaguchi T, Minematsu K, Omae T : The J-curve phenomenon in stroke recurrence. Stroke 1993; 24: 1844–1849.
The INDANA Project Collaborators: Effect of antihypertensive treatment in patients having already suffered from stroke: gathering the evidence. Stroke 1997; 28: 2557–2562.
Tzourio C, Anderson C, Chapman N, et al, PROGRESS Collaborative Group : Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003; 163: 1069–1075.
Fransen M, Anderson C, Chalmers J, et al: Effects of a perindopril-based blood pressure-lowering regimen on disability and dependency in 6105 patients with cere brovascular disease: a randomized controlled trial. Stroke 2003; 34: 2333–2338.
Chapman N, Huxley R, Anderson C, et al: Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history. The PROGRESS trial. Stroke 2004; 35: 116–121.
Arakawa S, Saku Y, Ibayashi S, Nagao T, Fujishima M : Blood pressure control and recurrence of hypertensive brain hemorrhage. Stroke 1998; 29: 1806–1809.
Sawada T : What is asymptomatic cerebrovascular disease?— Its definition and diagnostic criteria. J Jpn Soc Intern Med 1997; 86: 725–732 ( in Japanese).
Committee for Writing New Guideline for Detection of Asymptomatic Brain Diseases: Guideline for Detection of Asymptomatic Brain Diseases 2003. Hokkaido, Japanese Society for Detection of Asymptomatic Brain Diseases, 2003 ( in Japanese).
Kobayashi S, Okada K, Koide H, Bokura H, Yamaguchi S : Subcortical silent brain infarction as a risk factor for clinical stroke. Stroke 1997; 28: 1932–1939.
Vermeer SE, Hollander M, van Dijk EJ, Hoffman A, Koudstaal PJ, Breteler MM : Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. Stroke 2003; 34: 1126–1129.
Vermeer SE, Prins ND, den Heijer T, Koudstaal PJ, Breteler MM : Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003; 348: 1215–1222.
Kinoshita T, Okudera T, Tamura H, Ogawa T, Hatazawa J : Assessment of lacunar hemorrhage associated with hypertensive stroke by echo-planar gradient-echo T2*-weighted MRI. Stroke 2000; 31: 1646–1650.
Kato H, Izumiyama M, Izumiyama K, Takahashi A, Itoyama Y : Silent cerebral microbleeds on T2*-weighted MRI: correlation with stroke subtype, stroke recurrence, and leukoaraiosis. Stroke 2002; 33: 1536–1540.
Leary MC, Saver JL : Annual incidence of first silent stroke in the United States: a preliminary estimates. Cerebrovasc Dis 2003; 16: 280–285.
Ishii M : Changes and prospects of antihypertensive drug therapy. J Jpn Coll Angiol 1997; 9: 551 ( in Japanese).
Matsuzawa Y, Hisamichi S, Kita T, Ozawa H, Yamamura T : Implication of major factors contributing to the development of arteriosclerosis, in: Annual Report of National Project Team Supported by the Research Grant for Comprehensive Measures against Work Related Diseases from the Ministry of Labor, Japan in 1995, 1996 ( in Japanese).
Staessen JA, Wang JG, Thijs L : Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001; 358: 1305–1315.
Moser M, Hebert P, Hennekens CH : An overview of the meta-analyses of the hypertension treatment trials. Arch Intern Med 1991; 151: 1277–1279.
The European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease Investigators: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782–788.
Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al: A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290: 2805–2816.
Kondo J, Sone T, Tsuboi H, et al: Effects of low-dose angiotensin II receptor blocker candesartan on cardiovascular events in patients with coronary artery disease. Am Heart J 2003; 146: E20.
Japanese Beta-Blockers and Calcium Antagonists Myocardial Infarction (JBCMI) Investigators: Comparison of the effects of beta blockers and calcium antagonists on cardiovascular events after acute myocardial infarction in Japanese subjects. Am J Cardiol 2004; 93: 969–973.
Sacks FM, Pfeffer MA, Moye LA, et al, for the Cholesterol and Recurrent Events Trial Investigators : The effect of pravastatin on coronary event after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001–1009.
Pedersen TR : Six-year follow-up of the Norwegian Multicenter Study on Timolol after acute myocardial infarction. N Engl J Med 1985; 313: 1055–1058.
The CAPRICORN Investigators: Effect of carvedilol on outcome after myocardial infarction in patients with leftventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001; 357: 1385–1390.
The Multicenter Diltiazem Postinfarction Trial Research Group: The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988; 319: 385–392.
Ishikawa K, Nakai S, Takenaka T, et al, on behalf of the Secondary Prevention Group : Short-acting nifedipine and diltiazem do not reduce the incidence of cardiac events in patients with healed myocardial infarction. Circulation 1997; 95: 2368–2373.
Ishikawa K, Kanamasa K, Hama J, et al: Effect of beta blocker on secondary prevention in elderly patients with post-myocardial infarction. Jpn J Geriat 1997; 34: 273–277 ( in Japanese).
Pfeffer MA, Braunwald E, Moye LA, et al, on behalf of the SAVE Investigators : Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial—the SAVE investigation. N Engl J Med 1992; 327: 669–677.
Pfeffer MA, McMurray JJ, Velazquez EJ, et al, Valsaltan in Acute Myocardial Infarction Trial Investigators : Valsaltan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893–1906.
Pitt B, Remme W, Zannad F, et al, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309–1321.
VA Cooperative Study Group on Hypertensive Agents: Effects of treatment on morbidity in hypertension. JAMA 1970; 213: 1143–1152.
The SOLVD Investigators: The effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293–302.
The SOLVD Investigators: The effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685–691.
Cohn JN, Tognoni G, Valsaltan Heart Failure Trial Investigators : A randomized trial of the angiotensin-receptor blocker valsaltan in chronic heart failure. N Engl J Med 2001; 345: 1667–1675.
Pfeffer MA, Swedberg K, Granger CB, et al, CHARM Investigators and Committees : Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759–766.
Granger CB, McMurray JJ, Yusuf S, et al, CHARM Investigators and Committees : Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362: 772–776.
Yusuf S, Pfeffer MA, Swedberg K, et al, CHARM Investigators and Committees : Effects of candesartan in patients with chronic heart failure and preserved left-ventricular systolic function: the CHARM-Preserved trial. Lancet 2003; 362: 777–781.
Packer M, Bristow MR, Cohn JN, et al, for the US Carvedilol Heart Failure Study Group: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334: 1349–1355.
Hjalmarson A, Goldstein S, Fagerberg B, et al, MERITHF Study Group : Effects of controlled-release metoprolol on total mortality, hospitalization, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Investigation Trial in Congestive Heart Failure (MERIT-HF). JAMA 2000; 283: 1295–1302.
CIBIS-II Investigators and Committees: The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomised trial. Lancet 1999; 353: 9–13.
Packer M, Coats AJ, Fowler MB, et al, Carvedilol Prospective Randomized Cumulative Survival Study Group : Effects of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651–1658.
Hunt SA, Baker DW, Chin MH, et al, Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure : ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation 2001; 104: 2996–3007.
Packer M, O'Connor CM, Ghali JK, et al, for the Prospective Randomized Amlodipine Survival Evaluation Study Group : Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996; 335: 1107–1114.
Verdecchia P, Schillaci G, Borgioni C, et al: Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998; 97: 48–54.
Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE : A meta-analysis of the effects of treatment on left ventricular mass in essential hypertention. Am J Med 2003; 115: 41–46.
Sato A, Hayashi M, Saruta T : Relative long-term effects of spironolactone in conjunction with an angiotensin-converting enzyme inhibitor on left ventricular mass and diastolic function in patients with essential hypertension. Hypertens Res 2002; 25: 837–842.
Gottdiener JS, Reda DJ, Massie BM, Materson BJ, Williams DW, Anderson RJ, for the VA Cooperative Study Group on Antihypertensive Agents : Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension. Circulation 1997; 95: 2007–2014.
Bakris GL, Williams M, Dworkin L, et al, National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group : Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 2000; 36: 646–661.
Klag MJ, Whelton PK, Randall BL, et al: Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 334: 13–18.
Tozawa M, Iseki K, Iseki C, Kinjo K, Ikemiya Y, Takishita S : Blood pressure predicts risk of development endstage renal disease in men and women. Hypertension 2003; 41: 1341–1345.
Voyaki SM, Staessen JA, Thijs L, et al, Systolic Hypertension in Europe (Syst-Eur) Trial Investigators : Followup of renal function in treated and untreated older patients with isolated systolic hypertension. J Hypertens 2001; 19: 511–519.
Vupputuri S, Batuman V, Muntner P, et al: Effects of blood pressure on early decline in kidney function among hypertensive men. Hypertension 2003; 12: 1144–1149.
Levey AS, Coresh J, Balk E, et al: National Kidney Foundation Practice Guideline for Chronic Kidney Disease, Evaluation, Classification, and Stratification. Ann Intern Med 2003; 139: 137–149.
Sarnak MJ, Levey AS, Schoolwerth AC, et al: Kidney disease as a risk factor for development of cardiovascular disease. Hypertension 2003; 11: 1050–1065.
Manjunath G, Tighiouart H, Coresh J, et al: Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int 2003; 63: 1121–1129.
Ruilope L, Salvetti A, Jamerson K, et al: Renal function and intensive lowering of blood pressure in hypertensive participants of the Hypertension Optimal Treatment (HOT) Study. J Am Soc Nephrol 2001; 12: 218–225.
Hillege HL, Girbes ARJ, Kam PJ, et al: Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000; 102: 203–210.
Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S : Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134: 629–636.
Manjunath G, Tighiouart H, Ibrahim H, et al: Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003; 41: 47–55.
Iseki K, Ikemiya Y, Iseki C, Takishita S : Proteinuria and the risk of developing end-stage renal disease. Kidney Int 2003; 63: 1468–1474.
Brown MJ, Palmer CR, Castaigne A, et al: Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the international Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366–372.
Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR, UKPDS Group : Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63: 225–232.
Gerstein HC, Mann JF, Yi Q, et al, HOPE Study Investigators : Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421–426.
Hillege HL, Fidler V, Diercks GF, et al, Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group : Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106: 1777–1782.
Tozawa M, Iseki K, Iseki C, Oshiro S, Ikemiya Y, Takishita S : Influence of smoking and obesity on the development of proteinuria. Kidney Int 2002; 62: 956–962.
Kambham N, Markowitz GS, Valeri AM, Lin J, D'Agati VD : Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 2001; 59: 1498–1509.
Orth SR : Smoking and the kidney. J Am Soc Nephrol 2002; 13: 1663–1672.
Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH : The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis. Ann Intern Med 1996; 124: 627–632.
Peterson JC, Adler S, Burkart JM, et al, The Modification of Diet in Renal Disease Study Group : Blood pressure control, proteinuria, and the progression of renal disease. Ann Intern Med 1995; 123: 754–762.
Jafar TH, Stark PC, Schmid CH, et al, AIPRD Study Group : Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition, a patient-level meta-analysis. Ann Intern Med 2003; 139: 244–252.
Wright JT Jr, Bakris G, Greene T, et al, African American Study of Kidney Disease and Hypertension Study Group : Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: result from the AASK trial. JAMA 2002; 288: 2421–2431.
Jafar TH, Stark PC, Schmid CH, et al, AIPRD Study Group : Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 2001; 60: 1131–1140.
Ruggenenti P, Perna A, Remuzzi G, The Investigators of the GISEN Group : Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int 2003; 63: 2254–2261.
Wilmer WA, Rovin BH, Hebert CJ, Rao SV, Kumor K, Hebert LA : Management of glomerular proteinuria, a commentary. J Am Soc Nephrol 2003; 14: 3217–3232.
De Zeeuw D, Remuzzi G, Parving H, et al: Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004; 65: 2309–2320.
Levey AS, Rocco MV : Clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43: S1–S268.
Lewis EJ, Hunsicker LG, Clarke WR, et al, Collaborative Study Group : Renoprotective effect of the angiotensinreceptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–860.
Parving HH, Lehnert H, Mortensen JB, Gomis R, Andersen S, Arner P, Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group : The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870–878.
Maschio G, Alberti D, Janin G, et al, The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group : Effects of the angiotensinconverting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334: 939–945.
The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 249: 1857–1863.
PROCOPA Study Group: Dissociation between blood pressure reduction and fall in proteinuria in primary renal disease, a randomized double-blind trial. J Hypertens 2002; 20: 729–737.
Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T : Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE), a randomised controlled trial. Lancet 2003; 361: 117–124.
Keane WF, Eknoyan G : Proteinuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis 1999; 35: 1004–1010.
Mangrum AJ, Bakris GL : Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: safety issue. Semin Nephrol 2004; 24: 168–175.
Hebert LA, Wilmer WA, Falkenhain ME, Ladson-Wofford SE, Nahman NS Jr, Rovin BH : Renoprotection: one or many therapies? Kidney Int 2001; 59: 1211–1226.
Kumagai H, Hayashi K, Kumamaru H, Saruta T : Amlodipine is comparable to angiotensin-converting enzyme inhibitor for long-term renoprotection in hypertensive patients with renal dysfunction: a one-year, prospective, randomized study. Am J Hypertens 2000; 9: 980–985.
Sato A, Hayashi K, Naruse M, Saruta T : Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003; 41: 64–68.
White WB, Duprez D, St Hillaire R, et al: Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003; 41: 1021–1026.
Committee for Statistical Survey, Japanese Society for Dialysis Therapy (Akiba T): The Current State of Chronic Dialysis Treatment in Japan (as of December 31, 2002). Tokyo, Japanese Society for Dialysis Therapy, 2003, p 12 ( in Japanese).
Zager PG, Nikolic J, Brown RH, et al: "U" curve association of blood pressure and mortality in hemodialysis patients. Kidney Int 1998; 54: 561–569.
Mazzuchi N, Carbonell E, Fernandes-Cean J : Importance of blood pressure control in hemodialysis patient survival. Kidney Int 2000; 58: 2147–2154.
Kimura G, Tomita J, Nakamura S, Uzu T, Inenaga T : Interaction between hypertension and other cardiovascular risk factors in survival of hemodialyzed patients. Am J Hypertens 1996; 9: 1006–1012.
Kikuchi K, Fukiyama K : Study of cardiac function in patients with dialysis, in: Annual Report of National Project Team for Long-Term Chronic Kidney Diseases (Chronic Renal Failure) (Chief, Kurokawa K), 1998, pp 49–54 ( in Japanese).
Nakamura S, Sasaki O, Nakahama H, Inenaga T, Kimura G : Left ventricular hypertrophy is a risk factor independent of hypertension in survival of hemodialyzed patients. Ren Fail 2002; 24: 175–186.
Kestenbaum B, Gillen DL, Sherrard DJ, Seliger S, Ball A, Stehman-Breen C : Calcium channel blocker use and mortality among patients with end-stage renal disease. Kidney Int 2002; 61: 2157–2164.
Foley RN, Herzog CA, Collins AJ : Blood pressure and long-term mortality in United States hemodialysis patients: USRDA waves 3 and 4 study. Kidney Int 2002; 62: 1784–1790.
Efrati S, Zaidenstein R, Dishy V, et al: ACE inhibitors and survival of hemodialysis patients. Am J Kidney Dis 2002; 40: 1023–1029.
Guerin AP, Blacher J, Pannier B, Matchais SJ, Safar ME, London GM : Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation 2001; 20: 987–992.
Shibasaki Y, Masaki H, Nishiue T, Nishikawa M, Matsubara H, Iwasaka T : Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. Nephron 2002; 90: 256–261.
Suzuki H, Nakamoto H, Okada H, Sugahara S, Kanno Y : A selective angiotensin receptor antagonist, valsartan, produced regression of left ventricular hypertrophy associated with a reduction of arterial stiffness. Adv Perit Dial 2003; 19: 59–66.
Saracho R, Martin-Malo A, Martinez I, Aljama P, Montenegro J : Evaluation of the Losartan in Hemodialysis (ELHE) Study. Kidney Int Suppl 1998; 68: S125–S129.
Wheat MW : Intensive drug therapy, in Doroghazi RM, Slater E (eds): Aortic Dissection. New York, McGraw-Hill, 1983, p 165.
Pretre R, von Segesser LK : Aortic dissection. Lancet 1997; 349: 1461–1464.
Nienaber CA, Eagle KA : Aortic dissection: new frontiers in diagnosis and management. Part II: Therapeutic management and follow-up. Circulation 2003; 108: 772–778.
Iimura O : Insulin resistance and hypertension in Japanese. Hypertens Res 1996; 19 ( Suppl I): S1–S8.
American Diabetes Association: Treatment of hypertension in adults with diabetes. Diabetes Care 2002; 25 ( Suppl 1): S71–S73.
UK Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713–720.
Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M : Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993; 118: 577–581.
Nakamura Y, Saitoh S, Takagi S, et al: Cardiovascular mortality based on blood pressure classification in patients with impaired glucose tolerance. J Clin Exp Med (Igaku No Ayumi) 2004; 210: 717–718 ( in Japanese).
Iimura O, Shimamoto K, Matsuda K, et al: Effects of angiotensin receptor antagonist and angiotensin converting enzyme inhibitor on insulin sensitivity in fructose-fed hypertensive rats and essential hypertensives. Am J Hypertens 1995; 8: 353–357.
The EUCLID Study Group: Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997; 349: 1787–1792.
Viberti G, Wheeldon NM, for the Micro Albuminuria Reduction with Valsartan (MARVAL) Study Investigators : Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus. A blood pressureindependent effect. Circulation 2002; 106: 672–678.
Hansson L, Lindholm LH, Niskanen L, et al: Effect of angiotensin converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611–616.
Tuomilehto J, Rastenyte D, Birkenhager WH, et al: Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension: N Engl J Med 1999; 340: 677–684.
Estacio RO, Jeffers BM, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW : The effect of nisoldipine as compared to enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 338: 645–652.
Tatti P, Pahor M, Byington RP, et al: Outcome results of the fosinopril versus amlodipine cardiovascular events randomised trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21: 597–603.
Matsuzaki M, Kita T, Mabuchi H, et al: Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia—Primary Prevention Cohort Study of the Japan Lipid Intervention Trial (J-LIT). Circ J 2002; 66: 1087–1095.
Sever PS, Dahlof B, Poulter NR, et al: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149–1158.
Health Promotion and Nutrition Division, Healthcare Department, Ministry of Health and Welfare: Present Status of Nutrition in Japan: Results from National Nutrition Survey in 1990. Tokyo, Dai-ichi Shuppan Publishing Co. Ltd., 1992, p 121 ( in Japanese).
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–2497.
Tanaka H, Teramoto S, Oashi K, et al: Effects of candesartan on cough and bronchial hyperresponsiveness in mildly to moderately hypertensive patients with symptomatic asthma. Circulation 2001; 104: 281–285.
Kiely DG, Cargill RI, Lipworth BJ : Effects of frusemide and hypoxia on the pulmonary vascular bed in man. Br J Clin Pharmacol 1997; 43: 309–313.
Fang J, Alderman MH : Serum uric acid and cardiovascular mortality. JAMA 2000; 283: 2404–2410.
Alderman MH, Cohen H, Madhaven S, Kivlighn S : Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 1999; 34: 144–150.
Choi HK, Atkinson K, Karlson EW, Whillett W, Curhan G : Alcohol intake and risk of incident gout in men: a prospective study. JAMA 2004; 363: 1277–1281.
Franse LV, Pahor M, Di Bari M, et al: Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program. J Hypertens 2000; 18: 1149–1154.
Yamanaka H, Togashi R, Hakoda M, et al: Optimal range of serum urate concentrations to minimize risk of gouty attacks during anti-hyperuricemic treatment. Adv Exp Med Biol 1998; 431: 13–18.
Guidelines Subcommittee: Hypertension and cardiovascular damage, in: Guidelines for the Management of Hyperuricemia and Gout, 1st ed. Tokyo, Japanese Society of Gout and Nucleic Acid Metabolism, 2002, pp 51–55 ( in Japanese).
Cheng JW, Zhu L, Gu MJ, Song ZM : Metaanalysis of propranolol effects on gastrointestinal hemorrhage in cirrhotic patients. World J Gastroenterol 2003; 9: 1836–1839.
Health and Welfare Statistics Association: Health condition, medical treatment and measure against common disease. Annual Statistical Report of National Health Conditions. J Health Welf Stat 1998; 45 ( Suppl): 81–111 ( in Japanese).
National High Blood Pressure Education Program Working Group: National High Blood Pressure Education Program Working Group report on hypertension in the elderly. Hypertension 1994; 23: 275–285.
Madhavan S, Ooi WL, Cohen H, Alderman MH : Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction. Hypertension 1994; 23: 395–401.
Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Pede S, Porcellati C : Ambulatory pulse pressure: a potent predictor of total cardiovascular risk in hypertension. Hypertension 1998; 32: 983–988.
Imai C, Muratani H, Kimura Y, Kanzato N, Takishita S, Fukiyama K : Effect of meal ingestion and active standing on blood pressure in patients ≥60 years of age. Am J Cardiol 1998; 81: 1310–1314.
Kannel WB, D'Agostino RB, Silbershatz H : Blood pressure and cardiovascular morbidity and mortality rates in the elderly. Am Heart J 1997; 134: 758–763.
Port S, Demer L, Jennrich R, Walter D, Garfinkel A : Systolic blood pressure and mortality. Lancet 2000; 355: 175–180.
Hayakawa T, Kita Y, Okamura T, Kadowaki T, Ueshima H : Cardiovascular medicine: NIPPON DATA. Med Frontline (Saishin Igaku) 2002; 57: 1360–1368 ( in Japanese).
Takagi S, Saito S, Sakamoto K, et al: Cerebral and cardiac complication and long-term prognosis of elderly hypertensive patients—from epidemiological study of cardiovascular disease in Hokkaido—. J Blood Press (Ketsuatsu) 1995; 5: 42–47 ( in Japanese).
Shimada K, Kawano A, Matsubayashi K, Nishinaga M, Kimura S, Ozawa T : Diurnal blood pressure variations and silent cerebrovascular damage in elderly patients with hypertension. J Hypertens 1992; 10: 875–878.
Bobrie G, Chatellier G, Genes N, et al: Cardiovascular prognosis of "masked hypertension" detected by blood pressure self-measurement in elderly treated hypertensive patients. JAMA 2004; 291: 1342–1349.
Amery A, Birkenhager W, Brixko P, et al: Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985; 1: 1349–1354.
Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO : Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338: 1281–1285.
MRC Working Party: Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992; 304: 405–412.
SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255–3264.
Staessen JA, Fagard R, Thijs L, et al: Randomised doubleblind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757–764.
Liu L, Wang JG, Gong L, Liu G, Staessen JA, for the Systolic Hypertension in China (Syst-China) Collaborative Group : Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. J Hypertens 1998; 16: 1823–1829.
Gong L, Zhang W, Zhu Y, et al: Shanghai trial of nifedipine in the elderly (STONE). J Hypertens 1996; 14: 1237–1245.
Insua JT, Sacks HG, Lau TS, et al: Drug treatment of hypertension in the elderly: a meta-analysis. Ann Intern Med 1994; 121: 355–362.
Gueyffier F, Bulpitt C, Boissel J-P : Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. Lancet 1999; 353: 793–796.
Ogihara T, Kuramoto K : Effect of long-term treatment with antihypertensive drugs on quality of life of elderly patients with hypertension: a double-blind comparative study between-calcium antagonist and a diuretic. NICSEH study. Hypertens Res 2000; 23: 33–37.
Ogihara T, on behalf of the PATE-Hypertension Study Group in Japan: A practitioner's trial on the efficacy of antihypertensive treatment in the elderly hypertension (the PATE-Hypertension Study) in Japan. Am J Hypertens 2000; 13: 461–467.
Wing LMH, Reid CM, Ryan P, et al: A comparison of outcomes with angiotensin converting enzyme inhibitors and diuretics in the elderly (the Second Australian National Blood Pressure Study). N Engl J Med 2003; 348: 583–592.
Black HR, Elliott WJ, Weber MA, et al, for the Stage I Systolic Hypertension (SISH) Study Group : One-year study of felodipine or placebo for stage I isolated systolic hypertension. Hypertension 2001; 38: 1118–1123.
Hakala SM, Tilvis RS, Strandberg TE : Blood pressure and mortality in an older population. A 5-year follow-up of the Helsinki Aging Study. Eur Heart J 1997; 18: 1019–1023.
Ogihara T, Morimoto S, Nakahashi T, et al: Therapeutic policy for elderly hypertensives in Japan—a questionnaire survey of specialists.. Jpn J Geriat 1994; 31: 396–403 ( in Japanese).
August P : Initial treatment of hypertension. N Engl J Med 2003; 348: 610–616.
Ogihara T, Hiwada K, Morimoto S, et al: Guidelines for treatment of hypertension in the elderly 2002 revised version. Hypertens Res 2003; 26: 1–36.
Perry HM Jr, Davis BR, Price TR, et al, for the Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group : Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP). JAMA 2000; 284: 465–471.
Kjeldsen SE, Kolloch RE, Leonetti G, et al, for the HOT Study Group : Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. J Hypertens 2000; 18: 629–642.
Somes GW, Pahor M, Shorr RI, Cushman WC, Applegate WB : The role of diastolic blood pressure when treating isolated systolic hypertension. Arch Intern Med 1999; 159: 2004–2009.
Hiwada K, Ogihara T, Matsumoto M, et al: Guidelines on treatment of hypertension in the elderly, 1999 revised edition. Jpn J Geriat 1999; 36: 576–603 ( in Japanese).
Messerli FH, Grossman E, Golgbourt U : Are ß-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 1998; 279: 1903–1907.
Hansson L, Lindholm LH, Ekbom T, et al: Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in old patients with hypertension-2 study. Lancet 1999; 354: 1751–1756.
Forette F, Seux ML, Staessen JA, et al: Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998; 352: 1347–1351.
Kuramoto K : Hypertension in the elderly and ACE inhibitor—study of age-related clinical efficacy and tolerability of captopril in 964 hypertensive patients in Japan. Intern Med (Naika) 1991; 68: 862–867 ( in Japanese).
Ogihara T, Hiwada K, Matsuoka H, et al: Guidelines on treatment of hypertension in the elderly, 1995—a tentative plan for comprehensive research projects on aging and health.. Jpn J Geriat 1996; 33: 945–975 ( in Japanese).
Ogihara T, Arakawa K : Clinical efficacy and tolerability of candesartan cilexetil. J Hum Hypertens 1999; 13 ( Suppl 1): S27–S31.
Kjeldsen SE, Dahlof B, Devereux RB, et al, for the LIFE Study Group : Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy. JAMA 2002; 288: 1491–1498.
Pitt B, Poole-Wilson PA, Segal R, et al, on behalf of the ELITE II Investigators : Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582–1587.
Black HR, Elliott WJ, Grandits G, et al, for the CONVINCE Research Group : Principal results of the controlled onset verapamil investigation of cardiovascular end points (CONVINCE) trial. JAMA 2003; 289: 2073–2082.
Yamamoto Y, Sonoyama K, Matsubara K, et al: The status of hypertension management in Japan in 2000. Hypertens Res 2002; 25: 717–725.
Katayama S, Inaba M, Morita T, Awata T, Shimamoto K, Kikkawa R : Blood pressure control in Japanese hypertensives with or without type 2 diabetes mellitus. Hypertens Res 2000; 23: 601–605.
Taler SJ, Textor SC, Augustine JE : Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension 2002; 39: 982–988.
Ohta Y, Tsuchihashi T, Fujii K, et al: Improvement of blood pressure control in a hypertension clinic: a 10-year follow-up study. J Hum Hypertens 2004; 18: 273–278.
Ono A, Fujita T : Factors relating to inadequate control of blood pressure in hypertensive outpatients. Hypertens Res 2003; 26: 219–224.
Nishizaka MK, Zaman MA, Calhoun DA : Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003; 16: 925–930.
Kaplan NM : Hypertensive crises, in: Clinical Hypertension, 8th ed. Baltimore, Lippincott Williams & Wilkins, 2002, pp 339–356.
Vaughan CJ, Delanty N : Hypertensive emergencies. Lancet 2000; 356: 411–417.
Sesoko S, Akema N, Matsukawa T, Kaneko Y : Predisposing factors for the development of malignant essential hypertension. Arch Intern Med 1987; 147: 1721–1724.
Ohta Y, Tsuchihashi T, Ohya Y, et al: Trends in the patho physiological characteristics of malignant hypertension. Hypertens Res 2001; 24: 489–492.
Kawazoe N, Eto T, Abe I, et al: Long-term prognosis of malignant hypertension; difference between underlying diseases such as essential hypertension and chronic glomerulonephritis. Clin Nephrol 1988; 29: 53–57.
Eagle KA, Berger PB, Calkins H, et al, Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery: ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2002; 105: 1257–1267.
Little JW : The impact on dentistry of recent advances in the management of hypertension. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000; 90: 591–599.
Tsuchihashi T, Takata Y, Kurokawa H, et al: Blood pressure response during dental surgery. Hypertens Res 1996; 19: 189–194.
Rosenthal T, Oparil S : Hypertension in women. J Hum Hypertens 2000; 14: 691–704.
Sato K : New proposal for hypertension in pregnancy. Nippon Ninnsin Chuudoku 2003; 11: 15–44 ( in Japanese).
Wallenburg HC : Prevention of pre-eclampsia: status and perspectives 2000. Eur J Obstet Gynecol Reprod Biol 2001; 94: 13–22.
Williams B, Poulter NR, Brown MJ, et al: Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004; 18: 139–185.
Roberts JM, Pearson G, Cutler J, Lindheimer M : Summary of the NHLBI working group on research on hypertension during pregnancy. Hypertension 2003; 41: 437–445.
Lewis R, Sibai BM : The use of calcium-channel blockers in pregnancy. New Horiz 1996; 4: 115–122.
Shotan A, Wiiderhorn J, Hurst A, Elkayam U : Risks of angiotensin-converting enzyme inhibition during pregnancy: experimental and clinical evidence, potential mechanisms, and recommendations for use. Am J Med 1994; 96: 451–456.
NMWR: Postmarketing surveillance for angiotensin-converting enzyme inhibitor use during the first trimester of pregnancy—United States, Canada, and Israel, 1987-1995. JAMA 1997; 277: 1193–1194.
Chasan-Taber L, Willett WC, Manson JE, et al: Prospective study of oral contraceptives and hypertension among women in the United States. Circulation 1996; 94: 483–489.
Anderson GL, Limacher M, Assaf AR, et al, Women's Health Initiative Steering Committee: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291: 1701–1712.
Staessen JA, Celis H, Fagard R : The epidemiology of the association between hypertension and menopause. J Hum Hypertens 1998; 12: 587–592.
Pines A, Fisman EZ : Hypertension in menopausal women—a special case, for special treatment? Gynecol Endocrinol 2001; 15: 397–405.
Fisman EZ, Tenenbaum A, Pines A : Systemic hypertension in postmenopausal women: a clinical approach. Curr Hypertens Rep 2002; 4: 464–470.
Uchiyama M : Studies of blood pressures in school children in Northern Japan. Public Health 1985; 99: 18–22.
Muntner P, He J, Cutler JA, Wildman RP, Whelton PK : Trends in blood pressure among children and adolescents. JAMA 2004; 291: 2107–2113.
Dillon MJ : Clinical aspects of hypertension, in Holliday MA (ed): Pediatric Nephrology. Baltimore, Williams & Wilkins, 1987, pp 743–757.
McCrory WW : Definition, prevalence, and distribution of causes of hypertension, in Loggie JMH (ed): Pediatric and adolescent Hypertension. Cambridge, Blackwell Scientific Publications, 1992, pp 104–111.
National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents: The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004; 114: 555–576.
Murata M : Hypertension. Jpn J Pediatr (Shonika Rinsho) 1986; 39 ( Suppl): 2977–2984 ( in Japanese).
Hashimoto N, Kawasaki T, Kikuchi T, Uchiyama M : Criteria of normal blood pressure and hypertension in Japanese preschool children. J Hum Hypertens 1997; 11: 351–354.
Uchiyama M, Kikuchi T, Yamauchi K, Murata M : Validity and problem of criterion measure of blood pressure in children of Japan. J Child Health (Shoni Hoken Kenkyu) 2004; 39: 174–176 ( in Japanese).
Abe K, Nishio T, Mori C, Haneda N, Watanabe K : A longitudinal study of blood pressure, cholesterol and left ventricular muscle volume in children: the Shimane Heart Study. Acta Paediatr Jpn 1993; 35: 130–137.
Daniels SR, Witt SA, Glascock B, Khoury PR, Kimball TR : Left atrial size in children with hypertension: the influence of obesity, blood pressure, and left ventricular mass. J Pediatr 2002; 141: 186–190.
Uchiyama M : Risk factors for the development of essential hypertension: long-term follow-up study in junior high school students in Niigata, Japan. J Hum Hypertens 1994; 8: 323–325.
Kawasaki T, Uezono K, Sanefuji M, et al: A 17-year follow-up study of hypertensive and normotensive male university students in Japan. Hypertens Res 2002; 26: 445–452.
Geleijnse JM, Hofman A, Witteman JCM, Hazebroek AA, Valkenburg HA, Grobbee DE : Long-term effects of neonatal sodium restriction on blood pressure. Hypertension 1997; 29: 913–917.
Martin RM, Ness AR, Gunnell SA, Emmett P, Smith GD : Does breastfeeding in infancy lower blood pressure in childhood? The Avon Longitudinal Study of Parents and Children (ALSPAC). Circulation 2004; 109: 1259–1266.
Research Committee on Serum Lipid Level Survey 1990 in Japan: Current state of and recent trends in serum lipid levels in the general Japanese population. J Atheroscler Thromb 1996; 2: 122–132.
Weiss R, Dziura J, Burgert T, et al: Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 2004; 350: 2362–2374.
Kotani K, Nishida M, Yamashita S, et al: Two decades of annual medical examinations in Japanese obese children: do obese children grow into obese adults? Int J Obes Relat Metab Disord 1997; 21: 912–921.
Naganuma Y, Tomizawa S, Igarashi K, Tooyama J, Ozawa K, Uchiyama M : Usefulness of 24-hour blood pressure measurement in obese children. J Pediatr Pract (Shonika Shinryo) 1996; 59: 2084–2088 ( in Japanese).
Tomizawa S, Uchiyama M, Kurayama H, et al: Study of the dose of long-acting nifedipine (Sepamit R) in hypertensive children with renal disease. J Pediatr Pract (Shonika Shinryo) 1996; 59: 303–310 ( in Japanese).
Ingelfinger JR : When should essential hypertension in childhood be treated and how? Pediatr Nephrol 1995; 9: 552.
Gifford RW : Evaluation of the hypertensive patient with emphasis on detecting curable causes. Milbank Mem Fund Q 1969; 47: 170–186.
Bech K, Hilden T : The frequency of secondary hypertension. Acta Med Scand 1975; 197: 65–69.
Ferguson RK : Cost and yield of the hypertensive evaluation. Ann Intern Med 1975; 82: 761–765.
Berglund G, Andersson O, Wilhelmsen L : Prevalence of primary and secondary hypertension: studies in a random population sample. BMJ 1976; 2: 554–556.
Danielson M, Dammstrom BG : The prevalence of secondary and curable hypertension. Acta Med Scand 1981; 209: 451–455.
Sinclair AM, Isles CG, Brown I, Cameron H, Murray GD, Robertson JWK : Secondary hypertension in a blood pressure clinic. Arch Intern Med 1987; 147: 1289–1293.
Omura M, Saita J, Yamaguchi K, Kakuta Y, Nishikawa T : Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res 2004; 27: 193–202.
Omae T : Pathophysiology and prognosis of hypertensive subjects. J Jpn Soc Intern Med (Nihon Naika Gakkai Zasshi) 1985; 74: 401–415 ( in Japanese).
Hypertension in Diabetes Study (HDS): 1 Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens 1993; 11: 309–317.
Dinneen SF, Gerstein HC : The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 1997; 157: 1413–1418.
Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M : Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type 2 diabetic patients. Ann Intern Med 1993; 118: 577–581.
Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R : Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1998; 128: 982–988.
Bretzel RG : Effects of antihypertensive drugs on renal function in patients with diabetic nephropathy. Am J Hypertens 1997; 10: 208S–217S.
Preston RA, Singer I, Epstein M : Renal parenchymal hypertension. Arch Intern Med 1996; 156: 602–611.
Nolin L, Courteau M : Management of IgA nephropathy: evidence-based recommendations. Kidney Int Suppl 1999; 70: S56–S62.
Maschio G, Cagnoli L, Claroni F, et al: ACE inhibition reduces proteinuria in normotensive patients with IgA nephropathy: a multicentre, randomized, placebo-controlled study. Nephrol Dial Transplant 1994; 9: 265–269.
Higashihara E : Clinical guideline of autosomal dominant polycystic kidney disease (ADPKD). Kidney (Jinzo) 2003; 26: 71–81 ( in Japanese).
Mizoguchi M, Tamura T, Yamaki A, Higashihara E, Shimizu Y : Genotypes of autosomal dominant polycystic kidney disease in Japanese. J Hum Genet 2002; 47: 51–54.
Higashihara E, Nutahara K, Kojima M, et al: Prevalence and renal prognosis of diagnosed autosomal dominant polycystic kidney disease in Japan. Nephron 1998; 80: 421–427.
Higashihara E, Aso Y, Shimazaki J, Ito H, Koise K, Sakai O : Clinical aspects of polycystic kidney disease. J Urol 1992; 147: 329–332.
Torres VE, Wilson DM, Burnett JC Jr, Johnson CM, Offord KP : Effect of inhibition of converting enzyme on renal hemodynamics and sodium management in polycystic kidney disease. Mayo Clin Proc 1991; 66: 1010–1017.
Ecder T, Chapman AB, Brosnahan GM, Edelstein CL, Johnson AM, Schrier RW : Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis 2000; 35: 427–432.
Higashihara E : Reno-protective effect of anti-hypertensive drugs in autosomal dominant polycystic kidney disease (ADPKD) and preventive effects of PPARã agonist against progressive renal failure in ADPKD, in Tomino Y (ed): Annual Report of Progressive Renal Disease Research Committee Supported by the Ministry of Health, Labor, and Welfare of Japan in 2002. 2003, pp 73–76 ( in Japanese).
Ruggieri PM, Poulos N, Masaryk TJ, et al: Occult intracranial aneurysms in polycystic kidney disease: screening with MR angiography. Radiology 1994; 191: 33–39.
Yamashita T, Ito F, Iwakiri N, Mitsuyama H, Fujii S, Kitabatake A : Prevalence and predictors of renal artery stenosis in patients undergoing cardiac catheterization. Hypertens Res 2002; 25: 553–557.
Uzu T, Inoue T, Fujii T, et al: Prevalence and predictors of renal artery stenosis in patients with myocardial infarction. Am J Kidney Dis 1997; 29: 733–738.
Preston RA, Epstein M : Ischemic renal disease: an emerging cause of chronic renal failure and end-stage renal disease. J Hypertens 1997; 15: 1365–1377.
Tuttle KR : Screening for renal artery stenosis: hypertension and more. Am J Kidney Dis 1998; 32: 842–847.
Imai Y, Abe K, Otsuka Y, et al: Exaggerated response of renin secretion to captopril (SQ 14225) in renovascular hypertension. Jpn Heart J 1980; 21: 793–802.
Oei HY : Captopril renography. Early observation and diagnostic criteria. Am J Hypertens 1991; 4: 678S–684S.
Nally JV, Chen C, Fine E, et al: Diagnostic criteria of renovascular hypertension with captopril renography. A consensus statement. Am J Hypertens 1991; 4: 749S–752S.
Olin JW, Peidmonte MR, Young JR, DeAnna S, Grubb M, Childs MB : The utility of duplex ultrasound scanning of the renal arteries for diagnosing significant renal artery stenosis. Ann Intern Med 1995; 122: 833–838.
Radermacher J, Chavan A, Bleck J, et al: Use of Doppler ultrasonography to predict the outcome of therapy for renal-artery stenosis. N Engl J Med 2001; 344: 410–417.
Vasbinder GBC, Nelemans PJ, Kessels AGH, Kroon AA, de Leeuw PW, van Engelshoven JMA : Diagnostic tests for renal artery stenosis in patients suspected of having renovascular hypertension: a meta-analysis. Ann Intern Med 2001; 135: 401–411.
Sos TA : Angioplasty for the treatment of azotemia and renovascular hypertension in atherosclerotic renal artery disease. Circulation 1991; 83 ( Suppl I): I-162–I-166.
Tegtmeyer CJ : Percutaneous renal revascularization. Mayo Clin Proc 1995; 70: 1127–1129.
Bonelli FS, McKusick MA, Textor SC, et al: Renal artery angioplasty: technical results and clinical outcome in 320 patients. Mayo Clin Proc 1995; 70: 1041–1052.
Zeller T, Frank U, Muller C, et al: Predictors of improved renal function after percutaneous stent-supported angioplasty of severe atherosclerotic ostial renal artery stenosis. Circulation 2003; 108: 2244–2249.
Eardley KS, Lipkin GW : Atherosclerotic renal artery stenosis: is it worth diagnosing? J Hum Hypertens 1999; 13: 217–220.
Plouin P-F, Chatellier G, Darne B, Raynaud A, for the Essai Multicentrique Medicaments vs Angioplastie (EMMA) Study Group: Blood pressure outcome of angioplasty in atherosclerotic renal artery stenosis. A randomized trial. Hypertension 1998; 31: 823–829.
Soejima H, Ikegami K, Machida J, Yoshida M : Renovascular hypertension. Changes and prognosis of the surgical treatment. Jpn J Urol 1990; 81: 902–908 ( in Japanese).
Ichijo T, Yamamoto N, Ueshiba H, Miyachi Y : Epidemiology of adrenal incidentaloma. Clin Endocrinol (Horumon To Rinsho) 2004; 52: 43–53 ( in Japanese).
Tsunoda K, Watanabe T, Misawa S, et al: Long-term post-operative prognosis of aldosterone producing adenoma—study of 90 cases with a mean follow-up time of 11 years. J Jpn Coll Angiol 1993; 33: 149–153 ( in Japanese).
Nishimura M, Uzu T, Fujii T, et al: Cardiovascular complications in patients with primary aldosteronism. Am J Kidney Dis 1999; 33: 261–266.
Miyachi Y : Annual Report of Research Project for Disorders of Adrenocortical Hormone Production Supported by the Research Grants from the Ministry of Health and Welfare of Japan. 2001 ( in Japanese).
Shenker Y : Medical treatment of low-renin aldosteronism. Endocrinol Metab Clin North Am 1989; 18: 415–442.
Celen O, O'Brien MJ, Melby JC, Beazly RM : Factors influencing outcome of surgery for primary aldosteronism. Arch Surg 1996; 131: 646–650.
Kaplan NM : Primary aldosteronism, in: Clinical Hypertension, 7th ed. Baltimore, Williams & Wilkins, 1998, pp 365–382.
Yokoyama T, Shimamoto K, Iimura O : Mechanism of inhibition of aldosterone secretion by a Ca2+ channel blocker in patients with essential hypertension and patients with primary aldosteronism. Folia Endocrinol Jpn (Nippon Naibunpi Gakkai Zasshi) 1995; 71: 1059–1074 ( in Japanese).
Miura Y : Primary aldosteronism, in Sugimoto T, Omata M (eds): Internal Medicine, 6th ed. Tokyo, Asakura Shoten, 1995, pp 1462–1468 ( in Japanese).
Omata K, Sato T, Murakami O, Abe K, Sasano H : A case of primary aldosteronism with cortisol secretion from adenoma. Biomed Ther (Chiryogaku), 1994; 28: 1397–1400 ( in Japanese).
Miyamori I : A case of primary aldosteronism, in: Annual Report of Research Project for Disorders of Adrenocortical Hormone Production Supported by the Research Grants from the Ministry of Health and Welfare of Japan in 1995. 1996, pp 227–233 ( in Japanese).
Young S-C, Shionoiri H, Takasaki I, Kihara M, Gotoh E : Hypertensive complications in patients with primary aldosteronism. A retrospective study. Curr Ther Res 1991; 50: 317–325.
Nawata H : Cushing syndrome (adrenal), in: Annual Report of Research Project for Disorders of Adrenocortical Hormone Production Supported by the Research Grants from the Ministry of Health and Welfare of Japan in 1995. 1996, pp 234–240 ( in Japanese).
Nawata H, Demura H, Suda T, Takayanagi R : Adrenal preclinical Cushing syndrome, in: Annual Report of Research Project for Disorders of Adrenocortical Hormone Production Supported by the Research Grants from the Ministry of Health and Welfare of Japan in 1995. 1996, pp 223–236 ( in Japanese).
Annual Report of Research Project for Diencephalic-Pituitary Dysfunction Supported by the Research Grants from the Ministry of Health and Welfare of Japan in 1993. 1994, pp 237–322 ( in Japanese).
Nakao K : Pheochromocytoma, in: Annual Report of Research Project for Disorders of Adrenocortical Hormone Production Supported by the Research Grants from the Ministry of Health and Welfare of Japan in 1995. 1996, pp 257–259 ( in Japanese).
Miura Y, Yoshinaga K : Doxazosin: a newly developed, selective a1-inhibitor in the management of patients with pheochromocytoma. Am Heart J 1988; 116: 1785–1789.
Yoshinaga H, Miura Y, Sanoyama K, et al: Treatment for pheochromocytoma with doxazosin mesilate. Med Consult N Remedies (Shinryo To Shinyaku), 1988; 25: 1367–1390 ( in Japanese).
Kaplan NM : Pheochromocytoma (with a preface about incidental adrenal masses), in: Clinical Hypertension, 7th ed. Baltimore, Williams & Wilkins, 1998, pp 345–363.
Plouin PF, Chatellier G, Fofol I, Corvol P : Tumor recurrence and hypertension persistence after successful pheochromocytoma operation. Hypertension 1997; 292: 1133–1139.
Noshiro T, Honma H, Shimizu K, et al: Two cases of malignant pheochromocytoma treated with cyclophosphamide, vincristine and dacarbazine in a combined chemotherapy. Endocr J 1996; 43: 279–284.
Saito I, Ito K, Saruta T : The effect of age on blood pressure in hyperthyroidism. J Am Geriatr Soc 1985; 33: 19–22.
Ogihara T, Hata T, Maruyama A, et al: Blood pressure response to an angiotensin II antagonist in thyrotoxic patients with and without high blood pressure. Endocrinol Jpn 1980; 27: 223–227.
Saito I, Ito K, Saruta T : Hypothyroidism as a cause of hypertension. Hypertension 1983; 5: 112–115.
Brickman AS, Nyby MD : Parathyroid disease and hypertension, in Laragh JH, Brenner BM (eds): Hypertension: Pathophysiology, Diagnosis, and Management, 2nd ed. New York, Raven Press, 1995, pp 2263–2279.
Kaplan NM : Other forms of secondary hypertension, in: Clinical Hypertension, 7th ed. Baltimore, Williams & Wilkins, 1998, pp 396–406.
Ishikawa K : Takayasu disease with hypertension. Spectrum-specific syndrome series 12. Syndrome in circulatory organ. Jpn J Clin Med (Nihon Rinsho), 1996; 54 ( Suppl): 118–121 ( in Japanese).
Hashimoto H : Annual Report of Immunologic Diseases Research Committee, Intractable Angitis Subcommittee Supported by the Research Grants from the Ministry of Health and Welfare of Japan in 2001. 2002, pp 21–25 ( in Japanese).
Koide K : Epidemiologic study of aortitis syndrome: number of newly developed patients and their complications, in: Annual Report of Intractable Angitis Research Committee Supported by the Research Grants from the Ministry of Health and Welfare in 1994. 1994, pp 7–10 ( in Japanese).
Machida M, Sakuma M, Aoki H, Yasuda K : Long-term follow-up results of cardiac and large artery lesion complicated with Takayasu arteritis, in: Annual Report of Intractable Angitis Research Committee Supported by the Research Grants from the Ministry of Health and Welfare in 1993. 1993, pp 192–195 ( in Japanese).
Miyata T, Sato O, Koyama H, Shigematsu H, Tada Y : Long-term survival after surgical treatment of patients with Takayasu's arteritis. Circulation 2003; 108: 1474–1480.
Department of Disease Control and Prevention, Health Service Bureau, the Ministry of Health and Welfare (supervising ed): Periarteritis nodosa, in: Guideline for Diagnosis and Treatment for Intractable Diseases. Aichi, Roppou Publication. 1997, pp 107–115 ( in Japanese).
Tolo-Salgar OH, Steinberger J, Thomas W, Rocchini AP, Carpenter B, Moller JH : Long-term follow-up of patients after coarctation of the aorta repair. Am J Cardiol 2002; 89: 541–547.
Ross RD, Clapp SK, Gunther S, et al: Augmented norepinephrine and renin output in response to maximal exercise in hypertensive coarctectomy patients. Am Heart J 1992; 123: 1293–1299.
Bell GM : Intracranial disorders and hypertension, in Laragh JH, Brenner BM (eds): Hypertension: Pathophysiology, Diagnosis and Management, 2nd ed. New York, Raven Press, 1995, pp 2451–2458.
Morimoto S, Sasaki S, Takeda K, et al: Decrease in blood pressure and sympathetic nerve activity by microvascular decompression of the rostral ventrolateral medula in essential hypertension. Stroke 1999; 30: 1707–1710.
Johnson AG, Nguyen TV, Day RO : Do nonsteroidal antiinflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994; 121: 289–300.
Phillips BB, Joss JD, Mulhausen PL : Blood pressure elevation in a patients treated with salsalate. Ann Pharmacother 2002; 36: 624–627.
Whelton A : Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 1999; 106 ( Suppl 5B): S13–S24.
Fowles RE : Potential cardiovascular effects of COX-2 selective nonsteroidal anti-inflammatory drugs. J Pain Palliat Care Pharmacother 2003; 17: 27–50.
Sigurjonsdottir HA, Franzson L, Manhem K, Ragnarsson J, Sigurdsson G, Wallerstedt S : Liquorice-induced rise in blood pressure: a linear dose-response relationship. J Hum Hypertens 2001; 15: 549–552.
Sigurjonsdottir HA, Manhem K, Axelson M, Wallerstedt S : Subjects with essential hypertension are more sensitive to the inhibition of 11β-HSD by liquorice. J Hum Hypertens 2003; 17: 125–131.
Sato A, Funder JW, Okubo M, Kubota E, Saruta T : Glucocorticoid-induced hypertension in the elderly. Relation to serum calcium and family history of essential hypertension. Am J Hypertens 1995; 8: 823–828.
Whitworth JA, Mangos GJ, Kelly JJ : Cushing, cortisol, and cardiovascular disease. Hypertension 2000; 36: 912–916.
Saruta T : Mechanism of glucocorticoid-induced hypertension. Hypertens Res 1996; 19: 1–8.
Whitworth JA, Schyvens CG, Zhang Y, Andrews MC, Mangos GL, Kelly JJ : The nitric oxide system in glucocorticoid-induced hypertension. J Hypertens 2002; 20: 1035–1043.
Iuchi T, Akaike M, Mitsui T, et al: Glucocorticoid excess induces superoxide production in vascular endothelial cells and elicits vascular endothelial dysfunction. Circ Res 2003; 92: 81–87.
Pirpiris M, Sudhir K, Yeung S, Jennings G, Whitworth JA : Pressor responsiveness in corticosteroid-induced hypertension in humans. Hypertension 1992; 19: 567–574.
Luke RG : Mechanism of cyclosporine-induced hypertension. Am J Hypertens 1991; 4: 468–471.
Suzuki M, Gouya T : Survey for development of guideline for criteria of EPO use, in: Annual Report of Medical Research Committee on Renal Failure Supported by the Ministry of Health, Labor, and Welfare of Japan in 1992. 1993, pp 165–172 ( in Japanese).
Miyashita K, Tojo A, Kimura K, et al: Blood pressure response to erythropoietin injection in hemodialysis and predialysis patients. Hypertens Res 2004; 27: 79–84.
Kuriyama S, Hopp L, Yoshida H, et al: Evidence for amelioration of endothelial cell dysfunction by erythropoietin therapy in predialysis patients. Am J Hypertens 1996; 9: 426–431.
Ishimitsu T, Tsukada H, Ogawa Y, Numabe A, Yagi S : Genetic predisposition to hypertension facilitates blood pressure elevation in hemodialysis patients treated with erythropoietin. Am J Med 1993; 94: 401–406.
Hui KK : Hypertensive crisis induced by interaction of clonidine with imipramine. J Am Geriatr Soc 1983; 31: 164–165.
Abo-Zena RA, Bobek MB, Dweik RA : Hypertensive urgency induced by an interaction of mirtazapine and clonidine. Pharmacotherapy 2000; 20: 476–478.
About this article
Cite this article
Guidelines for the Management of Hypertension (JSH 2004). Japanese Society of Hypertension. Hypertens Res 29, S1–S105 (2006). https://doi.org/10.1038/hr.2006.143